Immunitybio is trading 4% down today at $7.42 as the company faces ongoing pressure from an FDA warning letter regarding promotional claims for its bladder cancer drug, Anktiva.
- The FDA letter cited allegedly false and misleading claims, which recently triggered a 20–30% single-day collapse in share price.
- Broader selling pressure across the biotech sector and major indices is further weighing on the stock as investors reassess regulatory risks.